ESC 365 - Long QT syndrome type 1 and type 2: which is the preferred gene therapy strategy?

EHRA Premium Access

Long QT syndrome type 1 and type 2: which is the preferred gene therapy strategy?

Session: Gene therapy for cardiac arrhythmias

Topic: Arrhythmias

Speaker: Doctor M. Ackerman (Rochester, US)

Event: EHRA 2024

Congress Presentation

Add to my library

About the speaker

Doctor Michael Ackerman

Mayo Clinic, Rochester (United States of America)

11 presentations

3 followers

4 more presentations in this session

Raising the bar: the role of preclinical models in the development of gene therapies for channelopathies

Speaker: Associate Professor C. Remme (Amsterdam, NL)

Gene therapy strategies for Brugada syndrome: targeting protein-trafficking regulator MOG1

Speaker: Professor Q. Wang (Wuhan, CN)

Gene therapy for atrial fibrillation: a dream come true?

Speaker: Professor K. Donahue (Worcester, US)

Discussion: my views on it

Speaker: Doctor A. Gomez (Orsay, FR)

Access the full session

Gene therapy for cardiac arrhythmias

Speakers: Doctor M. Ackerman, Associate Professor C. Remme, Professor Q. Wang, Professor K. Donahue, Doctor A. Gomez

About the event

EHRA 2024

7 April - 9 April 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources